McKesson (MCK) Q3 2024 Earnings
McKesson reported Q3 2024 revenue of $93.7B, beat analyst consensus of $89.3B by $4.3B. Diluted EPS came in at $7.07, beat the $6.88 consensus by $0.19. McKesson reports across 4 business segments, led by U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about McKesson's Q3 2024 earnings report.
McKesson (MCK) reported Q3 2024 earnings on November 6, 2024 after market close.
McKesson reported revenue of $93.7B and diluted EPS of $7.07 for Q3 2024.
Revenue beat the consensus estimate of $89.3B by $4.3B. EPS beat the consensus estimate of $6.88 by $0.19.
You can read the 10-Q periodic report (0000927653-24-000125) directly on SEC EDGAR. The filing index links above go to sec.gov.